Versartis Secures $25,000,000 Series C Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    500 Ellis Street Mountain View, CA 94043
  • Company Description
    Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    The primary use of the proceeds will be to fund clinical trials of its leadproduct, VRS-317, for growth hormone deficiency (GHD) in pediatric patients. VRS-317 is a proprietary once monthly form of recombinant humangrowth hormone (rhGH).
  • M&A Terms
  • Venture Investor
    Aisling Capital
  • Venture Investor
    Index Ventures
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    Advent Venture Partners

Trending on Xconomy